We are thrilled to announce that the highly anticipated N-Nitroso impurities of Amide and Indole have now been successfully developed e.g. N-Nitroso Orlistat , N-Nitroso Ropinirole , N-Nitroso Caprolactam ,N-Nitroso Gabapentin EP Impurity A , N-Nitroso Rizatriptan , N-Nitroso Zolmitriptan, N-Nitroso Naratriptan , N-Nitroso Tadalafil , N-Nitroso Eletriptan etc. are ready Stock
search icon
We are thrilled to announce that the highly anticipated N-Nitroso impurities of Amide and Indole have now been successfully developed e.g. N-Nitroso Orlistat , N-Nitroso Ropinirole , N-Nitroso Caprolactam ,N-Nitroso Gabapentin EP Impurity A , N-Nitroso Rizatriptan , N-Nitroso Zolmitriptan, N-Nitroso Naratriptan , N-Nitroso Tadalafil , N-Nitroso Eletriptan etc. are ready Stock

Menu

Nitroso

Nitrosamines are a group of chemical compounds that contain the nitroso functional group (NO) attached to an amine group (-NH). They can form in various ways, including through industrial processes, combustion, and certain chemical reactions, particularly involving nitrites and secondary amines. Nitrosamines are of concern because Many nitrosamines (N-Nitrosamines) are potent genotoxins; some have been classified as possible human carcinogens, although the degree of risk can vary depending on factors such as the amount of exposure and individual susceptibility. Synchemia Research Chemical is dedicated to thoroughly investigating the formation of nitroso impurities in APIs, including those related to the manufacturing processes. This approach indicates a proactive stance toward quality control and regulatory compliance. By exploring all potential sources of nitroso impurities, including those arising from the production processes themselves, Synchemia Research Chemical demonstrates a commitment to ensuring the purity, safety, and efficacy of their pharmaceutical products. Nitrosoamines, including N-Des-methyl Nitroso impurities, are important in pharmaceutical research and development due to their potential impact on drug safety and efficacy. Understanding and controlling the presence of these impurities is crucial for ensuring the quality and safety of pharmaceutical products. Can N-Nitrosamines exist in two different stable forms? N-nitrosamines substituted with two different alkyl groups can exist in two different stable forms distinguishable by several analytical methods. The two rotamers may differ in their overall dipole moment and therefore may posses different chemical and physical properties. Why do I see two peaks when analyzing N-Nitrosamines by HPLC or GC? HPLC and GC)analysis of N-nitrosamines may show two rotamers of the N-nitrosamine as two separate peaks. Whether two peaks are observed depends on the structure of the N-nitrosamine (i.e., symmetric vs. asymmetric) as well as the separation power of the analytical method.
We are the Synchemia Research Chemical specializes in manufacturing and exporting various nitrosoamine compounds, particularly focusing on N-Des-methyl Nitroso impurities of various APIs and nitroso compounds of direct APIs that contain secondary amines. By specializing in the synthesis and export of these compounds, Synchemia Research likely plays a significant role in supporting the pharmaceutical industry's efforts to meet regulatory requirements and ensure the highest standards of quality and safety in drug manufacturing.
download image Download catalogue

Pharmaceutical Reference Standards

N-Nitroso Omadacycline Impurity 12
N-Nitroso Omadacycline Impurity 12
CAT No SRC-N0143555
CAS No NA
Mol.F. C25H32N6O8
Mol.Wt. 544.57 g/mole
INV STATUS CUSTOM SYNTHESIS
N-Nitroso Brexpiprazole Impurity
N-Nitroso Brexpiprazole Impurity
CAT No SRC-N0143556
CAS No 2761668-93-1
Mol.F. C20H19N3OS2
Mol.Wt. 381.5 g/mole
INV STATUS CUSTOM SYNTHESIS
N-Nitroso Metamizole EP Impurity E
N-Nitroso Metamizole EP Impurity E
CAT No SRC-N0143557
CAS No NA
Mol.F. C12H13N4O5S : Na
Mol.Wt. 325.3 : 23.0g/mole
INV STATUS CUSTOM SYNTHESIS
N-Nitroso Metamizole Impurity 2
N-Nitroso Metamizole Impurity 2
CAT No SRC-N0143558
CAS No NA
Mol.F. C12H14N4O5S
Mol.Wt. 326.3 g/mole
INV STATUS CUSTOM SYNTHESIS
Pentazocine Nitroso Impurity 1
Pentazocine Nitroso Impurity 1
CAT No SRC-N0143559
CAS No NA
Mol.F. C14H18N2O2
Mol.Wt. 246.3 g/mole
INV STATUS CUSTOM SYNTHESIS
N-Nitroso Metamizole EP Impurity A
N-Nitroso Metamizole EP Impurity A
CAT No SRC-N0143560
CAS No NA
Mol.F. C12H12N4O3
Mol.Wt. 260.25 g/mole
INV STATUS CUSTOM SYNTHESIS
N-Nitroso Metamizole Impurity 1
N-Nitroso Metamizole Impurity 1
CAT No SRC-N0143561
CAS No NA
Mol.F. C11H9N5O4
Mol.Wt. 275.22 g/mole
INV STATUS CUSTOM SYNTHESIS
N-(1-benzyl-4-methylpiperidin-3-yl)-N-methylnitrous amide
N-(1-benzyl-4-methylpiperidin-3-yl)-N-methylnitrous amide
CAT No SRC-N0143562
CAS No NA
Mol.F. C14H21N3O
Mol.Wt. 247.34 g/mol
INV STATUS IN STOCK
1-nitrosoazepan-4-one
1-nitrosoazepan-4-one
CAT No SRC-N0143563
CAS No NA
Mol.F. C6H10N2O2
Mol.Wt. 142.16 g/mole
INV STATUS IN STOCK
(1-Nitrosoazepan-4yl)benzozide
(1-Nitrosoazepan-4yl)benzozide
CAT No SRC-N0143564
CAS No NA
Mol.F. C13H17N5O
Mol.Wt. 259.31 g/mol
INV STATUS UNDER SYNTHESIS
N-Nitroso Thiamazole EP Impurity A
N-Nitroso Thiamazole EP Impurity A
CAT No SRC-N0143565
CAS No 111348-65-3
Mol.F. C5H12N2O3
Mol.Wt. 148.2 g/mole
INV STATUS IN STOCK
N-Nitroso-2-(ethylamino)-1-phenyl-1-propanone
N-Nitroso-2-(ethylamino)-1-phenyl-1-propanone
CAT No SRC-N0143566
CAS No NA
Mol.F. C11H14N2O2
Mol.Wt. 206.24 g/mol
INV STATUS IN STOCK
Phenoxybenzamine Nitroso Impurity 1
Phenoxybenzamine Nitroso Impurity 1
CAT No SRC-N0143567
CAS No NA
Mol.F. C11H16N2O3
Mol.Wt. 224.3 g/mole
INV STATUS IN STOCK
N-Nitroso Mefenamic Acid (USP)
N-Nitroso Mefenamic Acid (USP)
CAT No SRC-N0143568
CAS No 2114-63-8
Mol.F. C15H14N2O3
Mol.Wt. 270.3 g/mole
INV STATUS IN STOCK
Nitrosamines Impurity 90 | N-Nitroso ten methyl ester
Nitrosamines Impurity 90 | N-Nitroso ten methyl ester
CAT No SRC-N0143569
CAS No 60096-51-7
Mol.F. C6H10N2O4
Mol.Wt. 174.2 g/mole
INV STATUS IN STOCK
N-methyl-N-(pyridin-4-ylmethyl)nitrous amide
N-methyl-N-(pyridin-4-ylmethyl)nitrous amide
CAT No SRC-N0143570
CAS No 6335-95-1
Mol.F. C7H9N3O
Mol.Wt. 151.17 g/mol
INV STATUS UNDER SYNTHESIS

Let’s advance your research together.

Partner with us for specialized chemical materials and synthesis services that enable pharmaceutical innovation.